cc-486
Showing 1 - 16 of 16
Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma Trial in Tampa (CC-486, Duvelisib)
Recruiting
- Non Hodgkin Lymphoma
- +3 more
- CC-486
- Duvelisib
-
Tampa, FloridaMoffitt Cancer Center
Aug 15, 2022
Follicular Lymphoma Trial in Chicago (Venetoclax, Obinutuzumab, CC-486)
Recruiting
- Follicular Lymphoma
- Venetoclax
- +2 more
-
Chicago, IllinoisUniversity of Chicago Medical Center
Nov 12, 2021
MDS, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Australia (Azacitidine, CC-486)
Active, not recruiting
- Myelodysplastic Syndromes
- +2 more
- Azacitidine
- CC-486
-
Newcastle, New South Wales, Australia
- +10 more
Mar 29, 2022
Hematologic Tumor, Tumors Trial in Gainesville, Baltimore, Houston (CC-486)
Active, not recruiting
- Hematologic Neoplasm
- Neoplasms
- CC-486
-
Gainesville, Florida
- +2 more
Dec 2, 2021
Acute Myelogenous Leukemia (AML) Trial in Summit (CC-486)
Approved for marketing
- Acute Myelogenous Leukemia (AML)
- CC-486
-
Summit, New JerseyCelgene
Sep 16, 2020
Leukemia, Myeloid, Acute Trial in China (CC-486, Placebo)
Not yet recruiting
- Leukemia, Myeloid, Acute
- CC-486
- Placebo
-
Hefei, Anhui, China
- +31 more
Jun 7, 2022
MDS, CMML Trial in Florence (CC-486)
Recruiting
- MDS
- CMML
- CC-486
-
Florence, ItalyAOU Careggi- University of Florence
Mar 16, 2021
NSCLC Trial in Worldwide (CC-486, Pembrolizumab, Placebo)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- CC-486
- +2 more
-
Glendale, Arizona
- +32 more
Jan 21, 2022
NSCLC Trial in Worldwide (nab-paclitaxel IV, CC-486, Duravalumab)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- nab-paclitaxel IV
- +2 more
-
San Francisco, California
- +33 more
Jan 24, 2022
Myeloid Malignancies Trial in Australia, United Kingdom, United States (Magrolimab, Azacitidine, Venetoclax)
Recruiting
- Myeloid Malignancies
- Magrolimab
- +6 more
-
Birmingham, Alabama
- +12 more
Apr 6, 2022
Urinary Bladder Tumors, Carcinoma, Transitional Cell, Ovarian Tumors Trial in Worldwide (CC-486, Carboplatin, ABI-007)
Completed
- Urinary Bladder Neoplasms
- +7 more
- CC-486
- +2 more
-
Scottsdale, Arizona
- +12 more
Nov 7, 2019
Leukemia, Myeloid, Acute, MDS Trial in United Kingdom, United States (CC-486)
Completed
- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
- CC-486
-
New York, New York
- +4 more
Oct 22, 2018